natgillin/translations-raw huggingface dataset:
• The role and use of the Prescriber Checklist sticker included in the product package to document the established pregnancy status prior to dosing. 
• Vlogo in uporabo kontrolnega seznama za predpisovalce zdravila, ki je vključen v pakiranje za evidentiranje ugotovljene nosečnosti pred dajanjem zdravila.
Telavancin inhibits cell wall biosynthesis by binding to late-stage peptidoglycan precursors, including lipid II, which prevents polymerisation of the precursor into peptidoglycan and subsequent cross-linking events. 
Telavancin zavira biosintezo celične stene z vezavo na prekurzorje peptidoglikana pozne faze, vključno z lipidom II, ki preprečuje polimerizacijo prekurzorja v peptidoglikan in poznejše povezovalne dogodke.
Powder for concentrate for solution for infusion A white to pale pink, whole or fragmented cake 
prašek za koncentrat za raztopino za infundiranje Bela do bledo roza pogača, cela ali zdrobljena
4.7 Effects on ability to drive and use machines Dizziness, somnolence, confusion and blurred vision may occur and VIBATIV may have an influence on the ability to drive and use machines (see section 4.8). 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Pojavijo se lahko omotica, somnolenca, zmedenost in zamegljen vid in zdravilo VIBATIV lahko vpliva na sposobnost vožnje in upravljanja s stroji (glejte poglavje 4.8).
Genotoxicity was addressed with a standard in vitro and in vivo test battery. 
Genotoksičnost so ugotavljali z običajno in vitro in in vivo testno baterijo.
The tubular injury was characterised by degeneration and necrosis of proximal tubular cells, and was associated with increases in BUN and creatinine that reach a maximum of 2 times the control values at the highest doses. 
Značilnost tubularne poškodbe je degeneracija in nekroza proksimalnih tubularnih celic in je bila povezana s povišanjem BUN-ja in kreatinina, ki je dosegel dvakratni maksimum kontrolnih vrednosti najvišjega odmerka.
Patients who develop signs and symptoms of impaired hearing or disorders of the inner ear during treatment with telavancin should be carefully evaluated and monitored (see section 4.8). 
Bolnike, ki med zdravljenjem s telavancinom razvijejo znake in simptome okvare sluha ali bolezni notranjega ušesa, je treba pozorno oceniti in nadzorovati (glejte poglavje 4.8).
• That patients' renal function should be assessed and monitored and initial dose and dosage adjustments should be calculated based on the creatinine clearance. 
• Oceniti in spremljati je treba delovanje ledvic, začetni odmerek in prilagoditve odmerka pa je treba izračunati na podlagi očistka kreatinina.
In the liver, treatment for 13 weeks or longer resulted in reversible degeneration/necrosis of hepatocytes accompanied by elevations in serum AST and ALT in rats and dogs. 
V jetrih je zdravljenje, dolgo 13 tednov ali dlje, vodilo do reverzibilne degeneracije/nekroze hepatocitov, skupaj s povišanjem seruma AST in ALT pri podganah in psih.
In a second study, 6 weeks of dosing was associated with sloughed testicular germ cells in the epididymis, indicative of testicular injury, and effects upon sperm quality and quantity were observed. 
V drugi študiji je bilo 6-tedensko dajanje odmerka povezano z odmrlimi bakterijskimi celicami v obmodku, kar je kazalo na testikularno poškodbo in ugotovljeni so bili učinki na kakovost in količino spermijev.
If you have any further questions on the use of this product, ask your doctor or pharmacist. 
Če imate še kakšna dodatna vprašanja v zvezi z uporabo tega izdelka, vprašajte svojega zdravnika ali
Male fertility was unaffected. 
Fertilnost samcev ni bila prizadeta.
Patients receiving telavancin in conjunction with or sequentially with other medicinal products with known ototoxic potential should be carefully monitored and the benefit of telavancin evaluated if hearing deteriorates. 
Bolnike, ki prejemajo telavancin v povezavi z drugimi zdravili oz. po drugih zdravilih z znanim ototoksičnim potencialom, je potrebno skrbno spremljati, korist telavancina pa oceniti, če se sluh poslabša.
• That Vibativ has a risk of nephrotoxicity including increased risk of mortality in patients with pre existing acute renal failure and is therefore contraindicated in patients with pre-existing acute renal failure and in patients with creatinine clearance < 30ml/min, including patients undergoing haemodialysis. 
• Pri zdravilu Vibativ obstaja tveganje za nefrotoksičnost, vključno s povečanim tveganjem smrtnosti pri bolnikih s predobstoječo akutno ledvično odpovedjo in je zato kontraindicirano pri bolnikih s predhodno akutno ledvično odpovedjo ter pri bolnikih z očistkom kreatinina < 30 ml/min, vključno z bolniki na hemodializi.
Telavancin also binds to bacterial membranes and causes depolarisation of membrane potential and an increase in membrane permeability that results in inhibition of protein, 
Telavancin se prav tako veže na bakterijske membrane in povzroča depolarizacijo potenciala membrane in povečanje prepustnosti membrane, kar zavira protein, RNK in
Effects on the kidney occurred after a minimum of 4 weeks of dosing and were a combination of renal tubular injury and tubular epithelial vacuolisation. 
Učinki na ledvice so se pojavili po najmanj 4 tednih dajanja odmerka in so bili kombinacija ledvične tubularne poškodbe in tubularne epitelialne vakuolizacije.
In healthy young adults, three hydroxylated metabolites were identified after infusion of telavancin. 
Pri zdravih mladih odraslih osebah so bili po infuziji telavancina identificirani trihidroksilirane metabolite.
What VIBATIV looks like and contents of the pack 
Izgled zdravila VIBATIV in vsebina pakiranja
However, no information is available on the use of haemodialysis to treat an overdose. 
Vendar pa podatki o uporabi hemodialize za zdravljenje prekomernega odmerjanja niso na voljo.
10 mg/kg every 24 hours 7.5 mg/kg every 24 hours *As calculated using the Cockcroft-Gault formula 
7,5 mg/kg vsakih 24 ur *Kot je bilo izračunano z uporabo formule Cockcroft-Gault.
However, the clearance of telavancin by CVVH has not been evaluated in a clinical study; thus, the clinical significance of this finding and use of CVVH to treat an overdose 
Vendar pa očistek telavancina z venovensko hemofiltracijo (CVVH) ni bil ocenjen v klinični študiji; zato klinični pomen te ugotovitve in uporabe venovenske hemofiltracije (CVVH) za zdravljenje prekomernega odmerjanja ni znan.
VIBATIV may cause side effects, such as dizziness, sleepiness, confusion or blurred vision that can have an influence on the ability to drive or operate machinery. 
Zdravilo VIBATIV lahko povzroči neželene učinke, kot so omotica, zaspanost, zmedenost ali zamegljen vid, ki imajo lahko vpliv na sposobnost vožnje in upravljanje strojev.
VIBATIV contains telavancin as active substance, which is an antibiotic of the glycopeptide group. 
Zdravilo VIBATIV vsebuje telavancin kot učinkovino, ki je antibiotik iz skupine glikopeptidov.
In phase 3 clinical trials involving 1680 patients (751 and 929, NP and cSSTI, respectively) who received telavancin at a daily dose of 10 mg/kg, adverse reactions were reported in 47.3% of patients. 
V kliničnih preskušanjih 3. faze, ki so vključevala 1680 bolnikov (751 z bolnišnično pljučnico in 929 s cSSTI), ki so prejemali telavancin v dnevnem odmerku 10 mg/kg, so poročali o neželenih učinkih pri 47,3 % bolnikov.
Renal function (serum creatinine and urinary output for oliguria/anuria) should be monitored daily for at least the first 3 to 5 days of therapy and every 48 to 72 hours thereafter in all patients receiving telavancin. 
Ledvično funkcijo (kreatinin v serumu in izločanje z urinom za oligourijo/anurijo) je potrebno vsakodnevno spremljati pri vseh bolnikih, ki prejemajo telavancin, vsaj prve 3 do 5 dni zdravljenja, zatem pa na vsakih 48 do 72 ur.
Mixing is continued until the content of the vial is completely dissolved and is free of particulate 
Mešanje poteka tako dolgo, dokler se vsebina viale popolnoma ne raztopi in pri pregledu s prostim
The effect of renal impairment on the pharmacokinetics of telavancin has been evaluated in 2 clinical pharmacology studies in healthy subjects with normal renal function and subjects with mild to severe renal impairment. 
Vpliv ledvične okvare na farmakokinetiko telavancina je bil ocenjen v 2 kliničnih farmakoloških študijah na zdravih osebah z normalno ledvično funkcijo ter osebah z blago do hujšo ledvično okvaro.
A reconstituted concentrate of VIBATIV is a clear, colourless to pale pink solution. 
Rekonstituirani koncentrat zdravila VIBATIV je čista, brezbarvna do svetlo roza raztopina.
In studies in healthy subjects, the pharmacokinetics of telavancin were not significantly altered by simultaneous administration of aztreonam or piperacillin-tazobactam. 
Pri študijah z zdravimi ljudmi se farmakokinetika telavancina ni bistveno spremenila pri istočasnemu jemanju aztreonama ali piperacilin-tazobaktama.
Based on their pharmacokinetic properties, no interaction is expected with other beta-lactams, clindamycin, metronidazole, or 
Na osnovi njihovih farmakokinetičnih značilnosti ni pričakovati interakcije z ostalimi betalaktami, klindamicinom, metronidazolom ali fluorokinoloni.
If renal function markedly decreases during treatment, the benefit of continuing telavancin should be assessed. 
Če se med zdravljenjem ledvična funkcija izrazito zmanjša, je treba oceniti korist v primeru nadaljevanja zdravljenja s
The Marketing Authorisation Holder shall ensure that all physicians who are expected to prescribe or use Vibativ are provided with a healthcare professional educational pack containing the following: 
Imetnik dovoljenja za promet z zdravilom vsem zdravnikom, za katere pričakuje, da bodo predpisovali ali uporabljali zdravilo Vibativ, zagotovi izobraževalni paket za zdravstvene delavce, ki vsebuje
Tell your doctor immediately if this is the case. 
To takoj povejte svojemu zdravniku.
6.6 Special precautions for disposal and other handling The powder must be reconstituted and the resulting concentrate must then be immediately diluted further prior to use. 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Prašek je potrebno rekonstituirati, dobljeni koncentrat pa je potrebno pred nadaljnjo uporabo takoj razredčiti.
Aseptic technique must be used to reconstitute VIBATIV. 
Za rekonstituiranje zdravila VIBATIV uporabljajte aseptično tehniko.
In embryo-fetal development studies malformations of digits and limbs were observed in rats, rabbits and minipigs. 
V študijah embrio-fetalnega razvoja je bila pri podganah, zajcih in morskih prašičkih ugotovljena spačenost prstov in udov.
The European Medicines Agency has deferred the obligation to submit the results of studies with telavancin in one or more subsets of the paediatric population in nosocomial pneumonia. 
Evropska agencija za zdravila je odstopila od obveze za predložitev rezultatov študij s telavancinom za vse skupine pediatrične populacije z bolnišnično pljučnico.
a ESRD= End-stage renal disease maintained on haemodialysis b Baseline mean creatinine clearance as calculated by Cockcroft-Gault equation 
a ESRD= ledvična bolezen v zadnjem stadiju, zdravljena s hemodializo b Izhodiščna vrednost za srednji očistek kreatinina, izračunano po enačbi Cockcroft-Gault
The MAH shall continue to monitor the activity of telavancin and the microbiological resistance as compared to other agents, through the longitudinal resistance surveillance program. 
Imetnik dovoljenja za promet z zdravilom bo še naprej spremljal delovanje telavancina in mikrobiološko odpornost v primerjavi z drugimi učinkovinami prek programa namenskega spremljanja odpornosti.
Telavancin was cleared by CVVH and the clearance of telavancin increased with increasing ultrafiltration rate. 
Telavancin se je očistil z venovensko hemofiltracijo (CVVH), očistek telavancina pa se je povečal s povišanjem hitrosti ultrafiltracije.
No data are available in subjects with severe hepatic impairment (Child-Pugh class C). 
Podatki o bolnikih s hudo okvaro jeter (Child-Pugh razred C) niso na voljo.
Blood samples for coagulation tests should be collected as closely as possible prior to a patient's next dose of telavancin or consideration given to using a test unaffected by telavancin. 
Krvni vzorci za teste koagulacije naj bodo odvzeti tik pred bolnikovim naslednjim odmerkom telavancina, v nasprotnem primeru pa je potrebno razmisliti o uporabi testa, na katerega telavancin ne vpliva.
Vacuolisation of tubular epithelium was a common observation in animals treated with the telavancin medicinal product and with the vehicle (HP-β-CD). 
Vakuolizacija tubularnega epitelija je bilo običajno opazovana pri živalih, zdravljenih z zdravilom telavancin in z nosilcem (HP-β-CD).
Microalbumin assays based on immunoassay utilizing nephelometric (turbidity) detection are not affected and can be used to monitor urinary protein excretion during telavancin treatment. 
Ni vpliva na analize mikroalbumina na osnovi imunološkega preskusa s pomočjo nefelometrične (turbidimetrične) meritve zato se lahko uporabijo za nadzor izločanja proteinov v urinu med zdravljenjem s telavancinom.
In the rat embryo-fetal development study dilatation of lateral ventricles of the brain was observed in the high dose group. 
V študiji embrio-fetalnega razvoja pri podganah je bila v skupinah z visokim odmerkom ugotovljena dilatacija stranskih prekatov možganov.
Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all antibacterial agents, including telavancin (see section 4.8), and may range in severity from mild to life-threatening. 
O kolitisu, povezanem z antibiotiki, in psevdomembranskem kolitisu so poročali pri skoraj vseh antibakterijskih sredstvih, vključno s telavancinom (glejte poglavje 4.8), ki lahko sega od blagega do takšnega, ki ogroža življenje.
Obese patients (defined as those with BMI > 30 kg/m2) should receive telavancin at the reduced dose of 7.5 mg/kg once every 24 hours (see section 5.2). 
Debeli bolniki (opredeljeni kot tisti z ITM > 30 kg/m2) prejmejo telavancin v zmanjšanem odmerku 7,5 mg/kg enkrat na 24 ur (glejte poglavje 5.2).
A clinical QTc study with telavancin doses of 7.5 and 15 mg/kg versus vehicle and an active comparator (400 mg moxifloxacin) showed that once daily dosing for 3 days resulted in a mean vehicle corrected increase in QTcF by 4.1 and 4.5 millisecond, respectively, compared to a 9.2 millisecond increase observed with the comparator. 
Klinična študija QTc z odmerkoma telavancina 7,5 in 15 mg/kg v primerjavi z vehiklom in aktivnem komparatorju (400 mg moksifloksacina) je pokazala, da je en dnevni odmerek za 3 dni povzročil srednje povišanje QTcF s popravkom medija za 4,1 in 4,5 milisekund v primerjavi z 9,2 milisekundnim povišanjem, ki je bilo opaženo pri komparatorju.
Telavancin may interfere with some laboratory tests that measure proteins in the urine. 
Telavancin lahko ovira nekatere laboratorijske teste, ki merijo beljakovine v urinu.
Also patients with baseline QTc >500 msec, congenital long QT syndrome, uncompensated heart failure, or abnormal K+ or Mg2+ blood levels that could not be corrected, severely neutropenic (absolute neutrophil count <500/mm3) or anticipated to develop severe neutropenia due to prior or planned chemotherapy, or who had HIV with CD4 count <100/mm3 during the last 6 months were excluded. 
Izključeni so bili tudi bolniki s QTc z izhodiščem >500 ms, kongenitalnim sindromom dolgega QT, nekompenzirano odpovedjo srca ali neobičajnimi vrednostmi K+ ali Mg2+ v krvi, ki jih ni bilo mogoče popraviti, hudo nevtropenijo (absolutno število nevtrofilcev <500/mm³) ali pri katerih se pričakuje, da bodo razvili hudo nevtropenijo zaradi predhodne ali načrtovane kemoterapije in tisti, ki so imeli HIV s številom CD4 <100/mm³ v zadnjih
The pharmacokinetics of telavancin have not been evaluated in severe hepatic impairment (Child-Pugh class C). 
Farmakokinetika telavancina ni bila ocenjena pri hujši jetrni okvari (Child-Pugh razred C).
Telavancin interferes with urine qualitative dipstick protein assays, as well as quantitative dye methods (e.g. pyrogallol red molybdate). 
Telavancin ovira kvalitativno analizo proteinov s testnimi lističi za urin in kvantitavnimi metodami obarvanja (npr. pirogalol rdeč molibdat).
Rapid intravenous infusions of antimicrobial agents of the class of glycopeptides have been associated with red man syndrome-like reactions, including flushing of the upper body, urticaria, pruritus or rash (see section 4.8). 
Hitre intravenske infuzije protimikrobnih sredstev iz razreda glikopeptidov so bile povezane z reakcijami podobnimi eritrodermu , vključno z rdečico na zgornjem delu telesa, urtikarijo, pruritusom ali izpuščaji (glejte poglavje 4.8).
In the pooled clinical studies (NP and complicated skin and soft tissue infection (cSSTI)), renal adverse reactions were reported more frequently in patients receiving telavancin compared with vancomycin (3.8% vs. 2.2%, respectively). 
V združenih kliničnih študijah (bolnišnična pljučnica in zapletene okužbe kože in mehkega tkiva (cSSTI)) so pogosteje poročali o neželenih učinkih na ledvicah pri bolnikih, ki so prejemali telavancin, kot pri bolnikih, ki so prejemali vankomicin (3,8 % proti 2,2 %).
Pharmacokinetic parameters (mean (SD)) following a single dose administration of 7.5 mg/kg telavancin in volunteers with varying degrees of renal function are provided below. 
Farmakokinetični parametri (povprečni (SD)) po enkratnem danem odmerku 7,5 mg/kg telavancina pri prostovoljcih z variirajočimi stopnjami ledvične funkcije so navedeni spodaj.
• That there is an identified risk of ototoxicity and patients developing ototoxicity signs or symptoms or patients receiving other medicinal products with ototoxic potential should be 
• Obstaja ugotovljeno tveganje za ototoksičnost ter da je treba bolnike, pri katerih se razvijejo znaki ali simptomi ototoksičnosti, oz. bolnike, ki prejemajo druga zdravila z ototoksičnim potencialom, skrbno oceniti in spremljati.
The other ingredients are hydroxypropylbetadex, mannitol (E421), sodium hydroxide (E524) (for pH adjustment) and hydrochloric acid (E507) (for pH adjustment). 
Druge sestavine so hidroksipropilbetadeks, manitol (E421), natrijev hidroksid (E524) (za uravnavanje pH) in klorovodikova kislina (E507) (za uravnavanje pH).
Following administration of a single 10 mg/kg dose of telavancin, the pharmacokinetics of telavancin in subjects with moderate hepatic impairment (Child-Pugh class B) were similar to that observed in subjects with normal hepatic function. 
Pri dajanju enojnega 10 mg/kg odmerka telavancina, je bila farmakokinetika telavancina pri osebah z zmerno jetrno okvaro (Child-Pugh razred B) podobna tisti, ugotovljeni pri osebah z običajno jetrno funkcijo.
A retrospective, chart review, post authorisation safety study (PASS) shall be conducted with the objective to further characterise the adverse drug reaction profile of telavancin when used in the clinical setting. 
Izvedena bo naknadna študija o varnosti zdravila po pridobitvi dovoljenja za promet z zdravilom (PASS) z namenom nadaljnje opredelitve profila o neželenih učinkih zdravila telavancin ob uporabi v kliničnem okolju.
Patients with renal impairment should receive an initial dose according to calculated or measured creatinine clearance as presented in the table below. 
Bolniki z ledvično okvaro prejmejo začetni odmerek glede na ocenjen ali izmerjen očistek kreatinina, kot je opisano v spodnji preglednici.
The clearance of telavancin by continuous venovenous haemofiltration (CVVH) was evaluated in an in vitro study. 
Očistek telavancina s kontinuirano venovensko hemofiltracijo (CVVH) je bil ocenjen z in vitro študijo.
If you also have other bacteria that cause your infection, your doctor may prescribe other antibiotics in 
Če vašo okužbo povzročajo tudi druge bakterije, vam lahko zdravnik poleg zdravila VIBATIV
• That there is a risk of infusion related reactions including red man syndrome-like reactions. 
• Obstaja tveganje za reakcije, povezane z infundiranjem, vključno z reakcijami, ki so podobne
Very common: may affect more than 1 in 10 people 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov)
Initial dose and dosage adjustments during treatment should be made based on calculated or measured creatinine clearance according to the dosing regimen in section 4.2. 
Začetni odmerek in prilagoditve odmerka med zdravljenjem je potrebno določiti glede na ocenjeni ali izmerjeni očistek kreatinina v skladu z režimom odmerjanja v poglavju 4.2.
In mixed infections where Gram-negative and/or certain types of anaerobic bacteria are suspected, VIBATIV should be co-administered with appropriate antibacterial agent(s). 
Pri mešanih okužbah, kjer obstaja sum na gramnegativne in/ali določene vrste anaerobnih bakterij, je treba poleg zdravila VIBATIV dajati tudi druga primerna antibakterijska
Telavancin may interfere with some laboratory tests that measure how well your blood is clotting. 
Telavancin lahko ovira nekatere laboratorijske teste, ki merijo strjevanje vaše krvi.
During treatment dose adjustments according to the table should be made based on calculated or measured creatinine clearance in patients with clinically relevant changes in renal function. 
Med zdravljenjem je potrebno prilagajati odmerek glede na preglednico, ki temelji na ocenjenem ali izmerjenem očistku kreatinina pri bolnikih s klinično pomembnimi spremembami ledvične funkcije.
As with other glycopeptides, ototoxicity (deafness and tinnitus) has been reported in patients treated with telavancin (see section 4.8). 
Kot pri ostalih glikopeptidih so tudi tukaj poročali o ototoksičnosti (gluhost in tinitus), pri bolnikih, ki so bili zdravljeni s telavancinom (glejte poglavje 4.8).
The nosocomial pneumonia (NP) studies excluded known or suspected pulmonary disease like granulomatous diseases, lung cancer, or other malignancy metastatic to the lungs; cystic fibrosis or active tuberculosis; Legionella pneumophila pneumonia; meningitis, endocarditis, or osteomyelitis; refractory shock defined as supine systolic blood pressure <90 mm Hg for >2 hours with evidence of hypoperfusion or requirement for high-dose sympathomimetic agents. 
Iz študij bolnišnične pljučnice so bile izključene znane pljučne bolezni in sumi nanje, kot so granulomatozne bolezni, pljučni rak ali druge maligne metastaze pljuč; cistična fibroza ali aktivna tuberkoloza, pljučnica Legionella pneumophila; meningitis, endokarditis ali osteomielitis; refraktorni šok, opredeljen kot počasen sistolični krvni pritisk <90 mm Hg za >2 uri z dokazano hipoperfuzijo ali potrebo po visokemu odmerku simpatomimetikov.
VIBATIV must be reconstituted and then further diluted prior to administration by intravenous infusion through a dedicated line or through a Y-site over a 60 minute period. 
Pred intravenskim infundiranjem je potrebno zdravilo VIBATIV rekonstituirati in nato nadalje razredčiti; infundiranje poteka po posebni cevki ali skozi Y-podaljšek v obdobju 60 minut.
Telavancin has no effect on platelet aggregation. 
Telavancin ne vpliva na agregacijo trombocitov.
Reconstituted concentrate must be further diluted prior to administration. 
Rekonstituirani koncentrat je potrebno nadalje razredčiti pred uporabo.
Your doctor will tell you if this is the case and may decide to monitor you more closely during treatment. 
Vaš zdravnik vas bo o tem obvestil in se lahko odloči, da vas bo med zdravljenjem podrobneje opazoval.
In studies on fertility in male rats, decreases in sperm motility and epididymal sperm counts as well as an increase in the frequency of abnormal sperm were demonstrated after 10 weeks of intravenous administration of telavancin. 
Pri študijah fertilnosti samcev podgan, se je po 10 tednih intravenskega odmerjanja telavancina pojavilo povečanje gibanja spermijev in števila spermijev v obmodku kakor tudi povečanje v pogostosti abnormalnih spermijev.
The mean (SD) maximum telavancin concentration (Cmax) amounts to 108 (26) µg/ml at steady state at a once daily dose of 10 mg/kg infused over a period of 1 h (tmax) and then falls to a trough value of 8.55 (2.84) µg/ml (C24h ). 
Povprečna (SD) najvišja koncentracija telavancina (Cmax) znaša 108 (26) µg/ml v stanju dinamičnega ravnovesja pri dnevnem odmerku 10 mg/kg infundiranem v času 1 ure (tmax), nato pa pada do najnižje vrednosti 8,55 (2,84) µg/ml (C24h).